Airdoc Technology ("Airdoc") was founded in September 2015. As a global market leader and pioneer in the field of AI-based retinal imaging, it endeavors to provide comprehensive and multi-faceted AI solutions for the early detection, auxiliary diagnosis and health risk assessment of chronic diseases. On November 5,2021, Airdoc was successfully listed on the Hong Kong Stock Exchange (stock code: 02251.HK) and became the first HK-listed medical AI company. Airdoc's innovative SaMD product approved for the auxiliary diagnosis of diabetic retinopathy was the first of its kind to obtain the class III medical device certificate from the National Medical Products Administration of the PRC, and it has been launched into use in medical institutions for auxiliary diagnosis. In addition, in order to meet the underserved healthcare needs, Airdoc has also developed a variety of pipeline products based on AI-empowered retinal imaging technologies. These products are now widely used in different scenarios such as community clinics, health checkup centers, insurance companies, optometry centers and pharmacies for auxiliary diagnosis and health risk assessment purposes. Headquartered in Beijing, Airdoc has subsidiaries and R&D centers in Beijing, Shanghai, Guangzhou, Shenzhen and HongKong. It also has set up offices in Nanjing, Xi'an, Chengdu and Wuhan. Thanks to its competitive advantages in the medical and technological fields as well as its social value, Airdoc has received a number of awards and recognitions, including Wu Wen Jun Artificial Intelligence Science and Technology Progress Award which is the highest AI award in China. With its mission of "More Intelligence, Better Care", Airdoc is working with its partners to provide high-quality healthcare services to everyone, aiming to make it as accessible as the air anytime and anywhere.